Golabi, Pegah

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review

Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023) · Hepatology

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 3,383

The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis

Younossi, Z. M., Golabi, P., de Avila, L., Paik, J. M., Srishord, M., Fukui, N., Qiu, Y., Burns, L., Afendy, A., & Nader, F. (2019) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 2,235

The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes

Younossi, Z. M., Golabi, P., Price, J. K., Owrangi, S., Gundu-Rao, N., Satchi, R., & Paik, J. M. (2024) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 416

Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)

Golabi, P., Otgonsuren, M., de Avila, L., Sayiner, M., Rafiq, N., & Younossi, Z. M. (2018) · Medicine

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 221

Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States

Golabi, P., Paik, J. M., Kumar, A., Al Shabeeb, R., Eberly, K. E., Cusi, K., GunduRao, N., & Younossi, Z. M. (2023) · Metabolism

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 113

Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis

Sayiner, M., Otgonsuren, M., Cable, R., Younossi, I., Afendy, M., Golabi, P., Henry, L., & Younossi, Z. M. (2017) · Journal of Clinical Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 76

Vigorous physical activity provides protection against all‐cause deaths among adults patients with nonalcoholic fatty liver disease (NAFLD)

Henry, A., Paik, J. M., Austin, P., Eberly, K. E., Golabi, P., Younossi, I., Henry, L., Gerber, L., & Younossi, Z. M. (2023) · Alimentary Pharmacology & Therapeutics

Liver Disease Diagnosis and TreatmentPhysical Activity and Health

Cited by 61

Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)

Golabi, P., Stepanova, M., Pham, H. T., Cable, R., Rafiq, N., Bush, H., Gogoll, T., & Younossi, Z. M. (2018) · BMJ Open Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 32

Factors Associated With Potential Progressive Course of Primary Biliary Cholangitis: Data From Real-world US Database

Younossi, Z. M., Stepanova, M., Golabi, P., Epstein, R. S., Strauss, M. E., Nader, F., & Racila, A. (2019) · Journal of Clinical Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 18